Evidence map›Paper›PMID 35370964›Full record

ArticleFrontiers in endocrinology2022

In Obese Patients With Type 2 Diabetes, Mast Cells in Omental Adipose Tissue Decrease the Surface Expression of CD45, CD117, CD203c, and FcϵRI.

David Lopez-Perez, Anaïs Redruello-Romero, Jesús Garcia-Rubio, Carlos Arana, Luis A Garcia-Escudero, Francisco Tamayo, Javier Salmeron, Julio Galvez, Josefa Leon, Ángel Carazo

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

David Lopez-PerezDepartment of Pharmacology, Faculty of Pharmacy, University of Granada, Granada, Spain.
Anaïs Redruello-RomeroResearch Unit, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain.
Jesús Garcia-RubioSurgery Unit, San Cecilio University Hospital, Granada, Spain.
Carlos AranaEndocrinology and nutrition department, Virgen de la Luz University Hospital, Cuenca, Spain.
Luis A Garcia-EscuderoDepartment of Statistics and Operative Research, Faculty of Sciences, University of Valladolid, Valladolid, Spain.
Francisco TamayoSurgery Unit, San Cecilio University Hospital, Granada, Spain.
Javier SalmeronGastroenterology Unit, San Cecilio University Hospital, Granada, Spain.
Julio GalvezDepartment of Pharmacology, Faculty of Pharmacy, University of Granada, Granada, Spain.
Josefa LeonResearch Unit, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain.
Ángel CarazoResearch Unit, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain.
Instituto de Investigación Biosanitaria de Granada · ESHospital Virgen de la Luz · ESUniversidad de Granada · ESUniversidad de Valladolid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The paradigm of mast cells in type 2 diabetes is changing. Although they were first considered deleterious inflammatory cells, now they seem to be important players driving adipose tissue homeostasis. Here we have employed a flow cytometry-based approach for measuring the surface expression of 4 proteins (CD45, CD117, CD203c, and FcϵRI) on mast cells of omental (o-WAT) and subcutaneous white adipose tissue (s-WAT) in a cohort of 96 patients with morbid obesity. The cohort was split into three groups: non-T2D, pre-T2D, and T2D. Noteworthy, patients with T2D have a mild condition (HbA1c <7%). In o-WAT, mast cells of patients with T2D have a decrease in the surface expression of CD45 (p=0.0013), CD117 (p=0.0066), CD203c (p=0.0025), and FcϵRI (p=0.043). Besides, in s-WAT, the decrease was seen only in CD117 (p=0.046). These results indicate that T2D affects more to mast cells in o-WAT than in s-WAT. The decrease in these four proteins has serious effects on mast cell function. CD117 is critical for mast cell survival, while CD45 and FcϵRI are important for mast cell activation. Additionally, CD203c is only present on the cell surface after granule release. Taking together these observations, we suggest that mast cells in o-WAT of patients with T2D have a decreased survival, activation capacity, and secretory function.

Indexed as

Diabetes Mellitus, Type 2Obesity, MorbidAdipose TissueHumansLeukocyte Common AntigensMast CellsPhosphoric Diester HydrolasesProto-Oncogene Proteins c-kitPyrophosphatasesReceptors, IgEENPP3 protein, humanKIT protein, humanLeukocyte Common AntigensPhosphoric Diester HydrolasesProto-Oncogene Proteins c-kitPTPRC protein, humanPyrophosphatasesReceptors, IgEadipose tissuebariatric surgeryflow cytometrymast cellobesitytype 2 diabetes

Identifiers

PMID35370964
PMCPMC8965342
OpenAlexW4220810574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.